Location Directory

Clinical trials in San Antonio, Texas

This page shows live ClinicalTrials.gov search results for San Antonio, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3164

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions: GTAEXS617, SoC; Drug
Lead sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Conditions: Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions: NC410, pembrolizumab; Drug
Lead sponsor: NextCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 17
States / cities: Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more

Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Interventions: CHS-114, toripalimab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more

Conditions: Neoplasm, Cancer, Malignant Tumors
Interventions: COM503, Zimberelimab; Drug
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: New Haven, Connecticut • Boston, Massachusetts • Grand Rapids, Michigan + 3 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions: HTD1801, Placebo; Drug
Lead sponsor: HighTide Therapeutics (Hong Kong) Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 43
States / cities: Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more

Conditions: Congenital Heart Disease (CHD)
Interventions: Umbilical Cord Clamping at ~30 seconds, Umbilical Cord Clamping at ~120 seconds, Umbilical Cord Milking; Procedure
Lead sponsor: Carl Backes, MD; Other
Eligibility: 37 Weeks to 42 Weeks
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 15 more

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions: BAY2862789; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Celebration, Florida • Detroit, Michigan • San Antonio, Texas

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Asthma, Allergic
Interventions: Dupilumab, House Dust Mites (HDM), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases, Hemoglobinopathies, Genetic Diseases, Inborn, Sickle Cell Anemia
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 2 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 9
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 5 more

Clinical trials in San Antonio, Texas

Filter and sort this location

Live official records

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Study of CHS-114 in Participants With Advanced Solid Tumors

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

Cord Clamping Among Neonates With Congenital Heart Disease

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

Dupilumab Effects Against Aeroallergen Challenge

A Long-term Follow-up Study in Participants Who Received CTX001